+34 679 490 537info@nanbiosis.com

Posts Taged ciber-bbn

NANBIOSIS in CIBER-BBN ANNUAL CONFERENCE 2017

CIBER-BBN will celebrate its 11th Annual Conference on November 13 and 14 in Santander. In these conference there will be a session dedicated to NANBIOSIS. Likewise, the annual meeting of the Scientific Technical Advisory Committee of NANBIOSIS will take place.

As in previous occasions, the meeting will serve to know the activity of NANBIOSIS, the Singular Technical Scientific Infrastructure (ICTS) of the CIBER-BBN and the Minimally Invasive Surgery Center Jesus Usón for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation.

As a novelty, it will be presented at the conference, the new internal structure, generated by NANBIOSIS for the development of “turnkey” projects in which, taking advantage of the complementarity and experience of its Units, NANBIOSIS offers complete service packages, with added value, adapted to the client’s needs, for applications such as nanotherapeutic agents, regenerative medicine, medical and diagnostic devices, among others. Some of the packages that are already designed or in more advanced stages will be explained, among which stands out the service of characterization and cascade assessment of nanomaterials that includes the characterization of the physicochemical attributes, their biological properties in vitro (immunology, toxicology and efficacy), and its in vivo compatibility (immunology, toxicology and efficacy), using appropriate animal models, with the possibility of being subject to regulatory conditions of Good Laboratory Practices. Some success stories of these “turnkey” projects developed in NANBIOSIS will be shown.

On this occasion, in addition, it is planned a presentation of EATRIS , the European Infrastructure for the Translation of Medicine, with which NANBIOSIS has initiated a line of collaboration.

Since its launch in July 2015, NANBIOSIS has received more than 550 access requests through its website, with an average participation of some 80 competitive projects per year and with an annual income for its services of between 2 and 3 million euros. Among its users, there are more than 100 companies.

Read More

2nd SUMMER SCHOOL OF EUROPEAN AND INTERNATIONAL SOCIETIES FOR NANOMEDICINE (ESNAM/ISNM)

The ESNAM / ISNM Summer School is co-organized by ESNAM and CIBER-BBN (led by Simó Schwartz, president of ESNAN and transfer manager of CIBER-BBN as well as Scientific Director of Unit 20 of NANBIOSIS).

The summer school is aimed at any student or professional interested in nanomedicine. It will count on the presence of speakers of recognized prestige in the area, among which are the Scientific Directors and Coordinators of several of the units of NANBIOSIS.

The ESNAM / ISNM Summer School will be held on 28-29 September 2017 at the Hospital Vall d’Hebron, Barcelona

The registration deadline with accommodation included ends on June 30

Program and registration details

Read More

The CIBER-BBN, partner of NANBIOSIS together with CCMIJU, incorporates two new research groups

The CIBER-BBN, partner of NANBIOSIS together with CCMIJU, has incorporated two new groups. One of them, led by José Miguel López-Higuera, is the Photonics Engineering Group of the University of Cantabria. The other is the Nanotechnology and Apoptosis Group of the Materials Science Institute of Aragon (CSIC-University of Zaragoza) led by Jesús Martínez de la Fuente. The incorporation of these groups has become official in the Governing Council of the CIBER celebrated on December, 1st

The CIBER-BBN currently has 47 research groups, selected on the basis of their scientific excellence, working mainly within three scientific programs: 1. Bioengineering and Medical Imaging, 2. Advanced Biomaterials and Therapies and 3. Nanomedicine. The activities of the center is oriented both to the development of prevention, diagnosis and monitoring systems and to the development of technologies related to specific therapies such as regenerative medicine and nanotherapies.

Jesús Martínez de la Fuente and the NAP group

The Group of Nanotechnology and Apoptosis (NAP) focuses its research on the development of general methodologies for the functionalization of nanoparticles and surfaces always looking for biotechnological applications.

Jesús Martínez de la Fuente is the author of about 150 articles in scientific journals of the highest level and inventor of 6 international patents, all licensed. He is an associate member of the Center for Cell Engineering of the University of Glasgow and of the Institute of Applied Sciences and Intelligent Systems of the Italian CNR in Naples and professor at the National Center for Translational Medicine (Shanghai Jiao Tong University, China). He is also co-founder and scientific advisor of the company NANOIMMUNOTECH S.L.

José Miguel López-Higuera and the Group of Photonic Engineering

The Photonics Engineering Group focuses its work on fiber optic sensor systems and instrumentation.
Prof. López-Higuera is a Fellow of the OSA, USA; Fellow of SPIE, USA, and member of the Royal Academy of Medicine of Cantabria. He is the Director of the International School of Light Sciences and Technologies that develops the fourth week of June of each year to the highest scientific and technological level in the world. He has made more than 600 academic and 17 industrial publications (patents). He has co-founded three technology-based companies.

The CIBER-BBN, partner of NANBIOSIS together with CCMIJU, incorporates two new research groups
Read More

Forum and Partnering CIBER-BBN with l’Università degli Studi di Torino

Next November 8, 2016 will be held at the Residence for Researchers of CSIC in Barcelona a meeting between researchers from NANBIOSIS Units and other CIBER-BBN researchers with researchers from the University of Torino.

This event is organized by NANBIOSIS and partially funded by the Ministry of Economy and Competitiveness through PRONANBIOSIS SAF2015-69388-REDI Project for ICTS.

The event consists of a series of presentations by the assistant research groups and B2B partnership, with more than 60 pre-arranged individual meetings and the possibility of organising new meetings after listening the presentations.

The final object is to interact to seek collaborations and promoting joint projects.

Nanbiosis - Forum and Partnering CIBER-BBN with l’Università degli Studi di Torino
Read More

CIBER-BBN, partner in the DRIVE project to develop biomaterials and Cell based treatments for diabetes

The CIBER-BBN is partner in a new EU consortium which receives €8.9 million funding to develop materials and cell based treatments for diabetes

Programme of research will be a game-changer for people with Type 1 diabetes and insulin-dependent Type 2 diabetes

Last June took place in Brussels the kick-off meeting of the European project DRIVE (Diabetes Reversing Implants with enhanced Viability and long-term Efficacy), consortium involves fourteen partners from seven European countries, has received €8.9 million funding as part of the Horizon 2020 – Research and Innovation Framework Programme.

The DRIVE programme will develop natural materials and new surgical devices to enhance the transplant and survival of insulin producing pancreatic islets for the treatment of diabetes. DRIVE project is co-ordinated by Dr. Garry Duffy, Department of Anatomy and Tissue Engineering Research Group, Royal College of Surgeons in Ireland. Prof. José Luis Pedraz, led of the Nanobiocel Group of CIBER-BBN in the Universidad del País Vasco (UPV/EHU) and coordinator of the Unit 10-Drug Formulation of NANBIOSIS, participates in this consortium.

Drive Project kick-off meeting

Drive Project kick-off meeting

Diabetes mellitus is a chronic disease characterised by high blood sugar (glucose).  If not treated carefully, diabetes causes several debilitating side effects including heart disease, damage to the eyes, kidneys and nerve endings (e.g. hands, feet) and can lead to premature death. The total number of people living with diabetes in Ireland is estimated to be over 225,000.  According to the international diabetes federation (IDF), 382 million people worldwide have diabetes and in 2013 an estimated 5.1 million deaths were attributable to the disease, representing 8.4% of global adult mortality. Blood glucose is high in diabetes because of the inability of the pancreas to produce sufficient insulin, a hormone that controls blood sugar. Currently the main treatment for diabetes is the daily injection of insulin. In patients where control is poor, transplantation of pancreatic cells (which contain insulin-producing β-cells) is possible. However there are challenges with this therapy including the short supply of donor pancreases, the need to use 3-4 pancreases to get enough β-cells for treatment and poor graft survival and retention at the transplant site.

The DRIVE consortium will address these challenges by developing a completely new system to deliver pancreatic β-cells effectively in a targeted and protected fashion. This will mean that fewer donor pancreases are needed for cell transplantation allowing more patients to avail of a more effective longer-lasting treatment with less demand on donor pancreases. Additionally, the consortium will investigate the combination of DRIVE’s technology with future stem cell-derived β-cells that will widen the availability of islet transplantation therapy to all insulin-dependent patients.

Dr. José Luis Pedraz, commented on the research funding: “We are delighted to participate in the DRIVE programme to translate new collaborative research for the benefit of patients with diabetes mellitus.  Regenerative medicine and stem cell therapies have the potential to revolutionise the treatment of patients who have diabetes, and through DRIVE we will develop new technologies to enhance stem cell therapies for these patients by increasing targeting and ease of delivery using advanced biomaterials.”

DRIVE’s β-System consists of a β-Gel, which contains the pancreatic β-cells within a pancreas mimicking gel; which itself is protected within a capsule called a β-shell. This is delivered using a specialised injection catheter, called β-cath, which offers a more minimally invasive surgical procedure than is currently used.

The current transplantation technique offers patients natural glucose control for 1-2 years. DRIVE’s β-system aims to provide control for up to 5 years by increasing the longevity of the β-cell transplant. The system offers further advantages through the slow release of immunosuppressant drugs by the β-shell, reducing the patient’s need for long-term anti-rejection medication, which has harmful side effects. The β-shell will also be retrievable, so it can be removed and replenished after the 5-year period. DRIVE’s 5-year work plan will include animal testing, with a view to human testing at the end of the project.

Professor Paul Johnson, Director of the Oxford Islet Transplant Programme and Professor of Paediatric Surgery at the University of Oxford, said: “Over the past 10 years, the transplantation of insulin-producing pancreatic cells known as islet cells (that can sense blood sugar levels and release insulin to maintain normal sugar levels) has achieved very promising results in adults who have developed the severest complications from insulin-dependent diabetes. The challenge is to now make sure that more people can benefit from this minimally-invasive treatment. Ultimately we would hope that it can be used to reverse diabetes in children soon after diagnosis. The DRIVE Consortium brings together some of the leading researchers in Europe in the fields of bioengineering, cell biology, and cell transplantation. The overall aim is to develop novel membranes to protect the transplanted islets from rejection ensure that islet transplantation can be undertaken without the need for the patient to take anti-rejection medication, with all the associated complications. This programme of research could be a real game-changer for people with Type 1 diabetes and the team in Oxford are very excited to be part of this state of the art research collaboration.”

The DRIVE Consortium represents a major interdisciplinary effort between stem cell biologists, experts in advanced drug delivery, research scientists, clinicians and research-active companies working together to develop novel therapeutics to address the challenges of treating diabtes. The researchers will optimise adult stem cell therapy using smart biomaterials and advanced drug delivery, and couple these therapeutics with minimally-invasive surgical devices.

Further Information about DRIVE

The project has recived funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 645991.

 Other partners include:

Royal College of Surgeon’s in Ireland (Ireland)

Dublin City University (Ireland)

Eberhard Karls University Tuebingen (Germany)

Utrecht University (The Netherlands)

University College Dublin (Ireland)

CIBER-BBN (Spain)

Abiel S.r.l. (Italy)

Contipro Pharma A.S.(Czech Republic)

Explora Biotech S.r.l. (Italy)

InnoCore Pharmaceuticals (The Netherlands)

Boston Scientific Ireland Ltd (Ireland)

INNOVA S.p.A. (Italy)

Ospedale Niguarda Ca’ Granda (Italy)

University of Oxford (UK)

Nanoencapsulated cells
Read More
Nanbiosis